

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT
LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY)
GRANTED ORPHAN DRUG DESIGNATION IN JAPAN

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Company.

The Company is pleased to announce that its Core Product, LBL-024 (Opamtistomig, a PD-L1/4-1BB bispecific antibody), has been granted orphan drug designation by Ministry of Health, Labour and Welfare (the “**MHLW**”) in Japan for the treatment of extrapulmonary neuroendocrine carcinoma (“**EP-NEC**”). This is the third orphan drug designation received by LBL-024, following those granted by the U.S. Food and Drug Administration (the “**FDA**”) and the European Commission (the “**EC**”), marking a further expansion of the global regulatory recognition of LBL-024 into a key Asian market.

Following the designation, LBL-024 will be eligible for a range of incentives in Japan, including subsidies for clinical development, guidance and advice from relevant authorities, priority consultation and priority review by the Ministry of Health, Labour and Welfare (the “**MHLW**”), reductions in consultation and marketing application fees, and an extension of the re-examination period. These incentives are expected to facilitate the development, registration and commercialization of LBL-024 in Japan.

Japan was the world’s fourth-largest pharmaceutical market in 2025, with a market size of over US\$73 billion. Its immuno-oncology market exceeded US\$8 billion, ranking behind only the United States, China and Europe. The entry of LBL-024 into this strategic market with Orphan Drug Designation not only represents a breakthrough for the EP-NEC indication but also means that the Company has established policy pathways for priority communication and expedited review within Japan’s regulatory framework, which will facilitate the subsequent development and registration of LBL-024 for other tumor indications in Japan.

Since October 2024, LBL-024 has successively received Breakthrough Therapy Designation from the National Medical Products Administration (the “NMPA”), Orphan Drug Designation and Fast Track Designation from the FDA, and Orphan Drug Designation in the European Union. In July 2026, the New Drug Application (the “NDA”) for LBL-024 was granted Priority Review by the NMPA. Currently, LBL-024 has demonstrated encouraging clinical activity and broad therapeutic potential in seven tumor types, namely EP-NEC (in first- and later-line settings), non-small cell lung cancer (“NSCLC”), small cell lung cancer (“SCLC”), biliary tract cancer (“BTC”), hepatocellular carcinoma (“HCC”), esophageal squamous cell carcinoma (“ESCC”) and ovarian cancer (“OC”). Results from multiple studies of LBL-024 in EP-NEC, NSCLC and BTC have been presented through oral and other scientific presentations at the annual meeting of the American Society of Clinical Oncology (the “ASCO”), the World Conference on Lung Cancer (the “WCLC”) and the congress of the European Society for Medical Oncology (the “ESMO”), among other leading international scientific conferences. The clinical results and innovative potential of LBL-024 have received broad recognition, further supporting its potential as an IO 2.0 cornerstone therapy with potential survival benefit in immunologically “cold tumors” and across a broad range of indications.

ABOUT LBL-024 (OPAMTISTOMIG)

LBL-024 is a bispecific antibody simultaneously targeting PD-L1 and 4-1BB, with the potential to become a pan-tumor IO 2.0 cornerstone therapy that offers survival benefits. To date, LBL-024 has been evaluated in clinical studies for 14 indications, including one pivotal single-arm registrational clinical study, one confirmatory Phase III clinical study and nine proof-of-concept studies, covering multiple major cancer types and “cold tumors.” Among the seven tumor types in which LBL-024 has been clinically validated, LBL-024 has demonstrated outstanding clinical value and broad therapeutic prospects, including extrapulmonary neuroendocrine carcinoma (EP-NEC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC) and ovarian cancer (OC).

Leveraging our self-developed X-body™ platform with full intellectual property rights, LBL-024 achieves conditional activation of 4-1BB, relieving PD-1/PD-L1 immunosuppression while enhancing 4-1BB regulated T-cell activation, achieving a synergistic effect in eliminating tumors. LBL-024 demonstrates a safety profile comparable to PD-1/PD-L1 inhibitors and greater potential for broad-spectrum cancer treatment. In particular, activation of 4-1BB can reactivate the exhausted T cells and substantially promote their proliferation, making 4-1BB-targeted therapies potentially suitable for the treatment of immunologically “cold tumors” that are resistant or unresponsive to PD-1/PD-L1 inhibitors, and may bring long-lasting survival benefits.

In October 2024, LBL-024 was granted Breakthrough Therapy Designation by the NMPA, and in November 2024, it received Orphan Drug Designation from the U.S. Food and Drug Administration (the “FDA”). In January 2026, LBL-024 was granted Fast Track Designation by the FDA and Orphan Drug Designation in the European Union. In July 2026, the Marketing Authorization Application of LBL-024 as an innovative biological product was included in the NMPA’s priority review and approval procedure and was formally accepted in August 2026. LBL-024 is expected to become the world’s first approved 4-1BB antibody drug, the world’s first approved agonistic antibody drug and the world’s first approved therapy targeting EP-NEC.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, LBL-024, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
*Chairman, Executive Director and
Chief Executive Officer*

Nanjing, PRC, September 28, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.